CDKN2A is one of the most commonly somatically mutated genes in pancreatic cancer [16], rare germline mutations have been found to be associated with increased risk of developing familiar pancreatic cancer [15, 17], and also CDKN2A promoter hyper-methylation has been suggested to play a critical role both in pancreatic cancer onset and prognosis [18]. The gene discussed is CDKN2A; the disease is familial pancreatic carcinoma.